Journal article icon

Journal article

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

Abstract:
Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels.

Methods A phase II randomized clinical trial of 123 patients with Her2-negative breast cancer was conducted, with patients treated with neoadjuvant chemother... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Human Genetics Wt Centre
Role:
Author
ORCID:
0000-0002-7572-3196
Publisher:
BioMed Central
Journal:
Genome medicine More from this journal
Volume:
92
Issue:
10
Publication date:
2018-11-29
Acceptance date:
2018-11-13
DOI:
ISSN:
1756-994X
Pmid:
30497530
Language:
English
Keywords:
Pubs id:
pubs:953457
UUID:
uuid:f84a5f0f-d359-4834-8cbb-a1e886098020
Local pid:
pubs:953457
Source identifiers:
953457
Deposit date:
2018-12-30

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP